34 / 64
Proyecto REHENOVA
26
11. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kid-
ney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis
Risk in Communities (ARIC) study. Circulation. 2011;123:2946-53.
12. Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. Popu-
lation pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in
patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost.
2011;9:2168-75.
13. Ficha técnica de Xarelto (rivaroxabán). Julio 2014.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000944/
WC500057108.pdf
14. Ficha técnica de Eliquis (apixabán). Julio 2014.
http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002148/
WC500107728.pdf
15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY
Steering Committee and Investigators. Dabigatran versus warfarin in patients with
atrial fibrillation. N Engl J Med. 2009;361:1139-51.
16. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal
impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban,
an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2012;70:703-12.
17. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy
of apixaban when compared with warfarin in relation to renal function in patients with
atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.
18. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G; American College
of Chest Physicians. Pharmacology and Management of the Vitamin K Antagonists.
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
(8th Edition). Chest. 2008;133:160S–98S.
19. Escolar Albadalejo G, Garcia Frade J, Lopez Fernandez MF, Roldan Schillling V. Guia
sobre los nuevos anticoagulantes orales. Sociedad Espanola de Hematologia y Hemo-
terapia/Sociedad Espanola de Trombosis y Hemostasia. Disponible en:
http://www.sehh.es/es/documentos/guias-y-documentos/1747-guia-sehh-seth-para-el-mane-
jo-de-los-nuevos-anticoagulantes-orales.html